Literature DB >> 24212417

[Current therapy of neuropathic pain].

M Schäfers1, T R Tölle.   

Abstract

Lesions of the nervous systems often result in difficult to treat pain syndromes. Neuropathic pain has increasingly gained attention from clinicians as a result of a better understanding of the underlying mechanisms and the development of proven analgesic therapies. This article provides an update on the diagnosis and treatment of neuropathic pain.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24212417     DOI： 10.1007/s00115-012-3623-5

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


  24 in total

1.  Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy.

Authors:  K J Ruhnau; H P Meissner; J R Finn; M Reljanovic; M Lobisch; K Schütte; D Nehrdich; H J Tritschler; H Mehnert; D Ziegler
Journal:  Diabet Med       Date:  1999-12       Impact factor: 4.359

Review 2.  Assessment and diagnosis of neuropathic pain.

Authors:  Ralf Baron; Thomas R Tölle
Journal:  Curr Opin Support Palliat Care       Date:  2008-03       Impact factor: 2.302

3.  Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.

Authors:  David J Rog; Turo J Nurmikko; Tim Friede; Carolyn A Young
Journal:  Neurology       Date:  2005-09-27       Impact factor: 9.910

4.  Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.

Authors:  Dan Ziegler; Alexander Ametov; Alexey Barinov; Peter J Dyck; Irina Gurieva; Phillip A Low; Ullrich Munzel; Nikolai Yakhno; Itamar Raz; Maria Novosadova; Joachim Maus; Rustem Samigullin
Journal:  Diabetes Care       Date:  2006-11       Impact factor: 19.112

Review 5.  Opioids for neuropathic pain.

Authors:  Nathaniel Katz; Christine Benoit
Journal:  Curr Pain Headache Rep       Date:  2005-06

6.  Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values.

Authors:  R Rolke; R Baron; C Maier; T R Tölle; - D R Treede; A Beyer; A Binder; N Birbaumer; F Birklein; I C Bötefür; S Braune; H Flor; V Huge; R Klug; G B Landwehrmeyer; W Magerl; C Maihöfner; C Rolko; C Schaub; A Scherens; T Sprenger; M Valet; B Wasserka
Journal:  Pain       Date:  2006-05-11       Impact factor: 6.961

7.  Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy.

Authors:  D Ziegler; M Hanefeld; K J Ruhnau; H Hasche; M Lobisch; K Schütte; G Kerum; R Malessa
Journal:  Diabetes Care       Date:  1999-08       Impact factor: 19.112

8.  Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB).

Authors:  Andrea L Cheville; Jeff A Sloan; Donald W Northfelt; Anand P Jillella; Gilbert Y Wong; James D Bearden Iii; Heshan Liu; Paul L Schaefer; Benjamin T Marchello; Bradley J Christensen; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2009-01-13       Impact factor: 3.603

9.  Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.

Authors:  Kristina B Svendsen; Troels S Jensen; Flemming W Bach
Journal:  BMJ       Date:  2004-07-16

10.  Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study"--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain.

Authors:  Solomon Tesfaye; Stefan Wilhelm; Alberto Lledo; Alexander Schacht; Thomas Tölle; Didier Bouhassira; Giorgio Cruccu; Vladimir Skljarevski; Rainer Freynhagen
Journal:  Pain       Date:  2013-05-31       Impact factor: 6.961
View more
  1 in total

1.  [Side effects of pain therapy : Sufficient analgesia without unnecessary complications].

Authors:  F Greul; A Zimmer; W Meißner
Journal:  Urologe A       Date:  2017-04       Impact factor: 0.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.